Interleukin-31: A Pro-inflammatory Oriented Cytokine
Type 2 immunity is represented by T helper 2 (Th2) lymphocytes and the cytokines produced downstream (Interleukin (IL)-4, IL-13, IL-31). They are increasingly recognized as pivotal mediators in the pathogenesis of immune-mediated dermatological conditions such as atopic dermatitis (AD) and psoriasis...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IMR Press
2025-06-01
|
| Series: | Frontiers in Bioscience-Landmark |
| Subjects: | |
| Online Access: | https://www.imrpress.com/journal/FBL/30/6/10.31083/FBL37462 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839636688358342656 |
|---|---|
| author | Giuseppe Murdaca Francesca Paladin Andrea Orsi Sebastiano Gangemi |
| author_facet | Giuseppe Murdaca Francesca Paladin Andrea Orsi Sebastiano Gangemi |
| author_sort | Giuseppe Murdaca |
| collection | DOAJ |
| description | Type 2 immunity is represented by T helper 2 (Th2) lymphocytes and the cytokines produced downstream (Interleukin (IL)-4, IL-13, IL-31). They are increasingly recognized as pivotal mediators in the pathogenesis of immune-mediated dermatological conditions such as atopic dermatitis (AD) and psoriasis (Pso). In these disorders, they initiate and amplify immunological signaling cascades, promote cutaneous inflammation, and contribute to the induction of pruritus. In this context, IL-33 and IL-31 would be believed to be intrinsically linked and related to the acuity of the disease. The presence of an interleukin could in fact trigger the other, amplifying the inflammatory process of itchy skin disorders and therefore the extent of the symptoms. High levels of IL-31 may support the maintenance of a microenvironment that promotes both the growth and spread of solid tumors, as well as the development of cancer-associated pruritus. Given these premises, non-histaminergic mediators such as IL-31 and IL-33 could be explored as novel therapeutic targets for the treatment of pruritus in immune-mediated skin diseases and cancer, improving the QoL of patients. Finally, we briefly discussed the recent innovations in the field of monoclonal anti-IL-31 therapies. |
| format | Article |
| id | doaj-art-d3f34b89c2574b5f95ab7bd0fddd9c59 |
| institution | Matheson Library |
| issn | 2768-6701 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | IMR Press |
| record_format | Article |
| series | Frontiers in Bioscience-Landmark |
| spelling | doaj-art-d3f34b89c2574b5f95ab7bd0fddd9c592025-07-07T09:22:57ZengIMR PressFrontiers in Bioscience-Landmark2768-67012025-06-013063746210.31083/FBL37462S2768-6701(25)01762-9Interleukin-31: A Pro-inflammatory Oriented CytokineGiuseppe Murdaca0Francesca Paladin1Andrea Orsi2Sebastiano Gangemi3Department of Internal Medicine, University of Genova, Viale Benedetto XV, 16132 Genova, ItalyElderly and Disabeld Department, San Paolo Hospital, 17100 Savona, ItalyDepartment of Health Sciences (DISSAL), University of Genova, 16132 Genova, ItalyDepartment of Clinical and Experimental Medicine, School and Operative Unit of Allergy and Clinical Immunology, University of Messina, 98125 Messina, ItalyType 2 immunity is represented by T helper 2 (Th2) lymphocytes and the cytokines produced downstream (Interleukin (IL)-4, IL-13, IL-31). They are increasingly recognized as pivotal mediators in the pathogenesis of immune-mediated dermatological conditions such as atopic dermatitis (AD) and psoriasis (Pso). In these disorders, they initiate and amplify immunological signaling cascades, promote cutaneous inflammation, and contribute to the induction of pruritus. In this context, IL-33 and IL-31 would be believed to be intrinsically linked and related to the acuity of the disease. The presence of an interleukin could in fact trigger the other, amplifying the inflammatory process of itchy skin disorders and therefore the extent of the symptoms. High levels of IL-31 may support the maintenance of a microenvironment that promotes both the growth and spread of solid tumors, as well as the development of cancer-associated pruritus. Given these premises, non-histaminergic mediators such as IL-31 and IL-33 could be explored as novel therapeutic targets for the treatment of pruritus in immune-mediated skin diseases and cancer, improving the QoL of patients. Finally, we briefly discussed the recent innovations in the field of monoclonal anti-IL-31 therapies.https://www.imrpress.com/journal/FBL/30/6/10.31083/FBL37462il-31il-33il-33/il-31 axisil-31 receptorscancer |
| spellingShingle | Giuseppe Murdaca Francesca Paladin Andrea Orsi Sebastiano Gangemi Interleukin-31: A Pro-inflammatory Oriented Cytokine Frontiers in Bioscience-Landmark il-31 il-33 il-33/il-31 axis il-31 receptors cancer |
| title | Interleukin-31: A Pro-inflammatory Oriented Cytokine |
| title_full | Interleukin-31: A Pro-inflammatory Oriented Cytokine |
| title_fullStr | Interleukin-31: A Pro-inflammatory Oriented Cytokine |
| title_full_unstemmed | Interleukin-31: A Pro-inflammatory Oriented Cytokine |
| title_short | Interleukin-31: A Pro-inflammatory Oriented Cytokine |
| title_sort | interleukin 31 a pro inflammatory oriented cytokine |
| topic | il-31 il-33 il-33/il-31 axis il-31 receptors cancer |
| url | https://www.imrpress.com/journal/FBL/30/6/10.31083/FBL37462 |
| work_keys_str_mv | AT giuseppemurdaca interleukin31aproinflammatoryorientedcytokine AT francescapaladin interleukin31aproinflammatoryorientedcytokine AT andreaorsi interleukin31aproinflammatoryorientedcytokine AT sebastianogangemi interleukin31aproinflammatoryorientedcytokine |